Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO1105 for Respiratory Syncytial Virus prevention
NCT07289503Phase 1Active, not recruiting
- Sponsor
- Abogen Bioscience
- Start
- May 2025
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABO1105 in respiratory syncytial virus infection (RSV) (3 cohorts), sponsored by Abogen Bioscience. Primary endpoints: Incidence of solicited adverse events and adverse reactions at 14 days and Incidence of unsolicited adverse events and adverse reactions at 30 days. Started May 2025; status: active, not recruiting.
02
Drugs
ABO1105
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07289503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289503.